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et	 al.	 (1961).	Tylosin	 is	 active	against	Gram-positive	
bacteria,	anaerobic	bacteria	and	mycoplasmas	(Giguere	
2006).	It	is	indicated	primarily	for	the	treatment	of	chronic	
respiratory	 disease	 complex	 caused	by	Mycoplasma 
gallisepticum and	synoviae	 in	chickens	and	 infectious	
sinusitis	in	turkeys	(Montesissa	et	al.	1999	,	Kowalski	et	
al.	2002).	On	the	other	hand,	it	is	prescribed	extensively	
for	 the	 treatment	 of	 bovine	 and	 swine	 respiratory	
infections	 (Taha	et	 al.	 1999,	Prats	 et	 al.	 2002,	Saurit	




Mycoplasmas	 are	 of	 considerable	 veterinary	
importance,	causing	infections	of	the	respiratory	and	
urogenital	 tracts,	mammary	 glands,	 joints	 and	 eyes	
of	poultry	and	livestock	species	(Hannan	et	al.	1997,	
Jordan	 et	 al.	 1998,	David	 2003,	Loria	 et	 al.	 2003).	
Tylosin	is	still	considered	as	one	of	the	most	effective	




Several	 pharmacokinetic	 studies	 have	 been	
reported	 for	 tylosin	 in	 cows	 and	buffalo	 (Gingerich	




industry,	 limited	 information	 is	 currently	 available	
about	 pharmacokinetic	 disposition	 of	 tylosin	 in	
broiler	chickens	(Kowalski	et	al.	2002).	Accordingly,	
the	 aim	 of	 the	 present	 study	was	 to	 determine	 the	








were	 used	 for	 oral	 administration.	Tylosin	 standard	
(Tylosin	 tartate,	 90	%,	 Sigma-Aldrich,	 St	 Louis,	
Περίληψη
	Η	φαρμακοκινητική	και	βιοδιαθεσιμότητα	δύο	σκευασμάτων	τυλοσίνης	χορηγούμενων	από	το	στόμα	πραγματοποιήθηκε	
σε	 κοτόπουλα	 κρεατοπαραγωγής	 με	 την	 μέθοδο	 απλής	 δόσης,	 τυχαιοποιημένου	 και	 παράλληλου	 σχεδιασμού.	 Τα	 δύο	
σκευάσματα	της	τυλοσίνης	(Tylosina®	και	Tylan®)	χορηγήθηκαν	από	το	στόμα	σε	δόση	25	mg/kg	σ.β.	μετά	από	νηστεία	
μιας	βραδιάς	 (n=15	κοτόπουλα/ομάδα).	Για	 τον	υπολογισμό	 της	βιοδιαθεσιμότητας	 της	 τυλοσίνης,	 δεκαπέντε	 επιπλέον	
κοτόπουλα	ορίστηκαν	ως	ομάδα	3	και	τους	χορηγήθηκε	μια	απλή	ενδοφλέβια	δόση	τυλοσίνης	25	mg/kg	σ.β.	Δείγματα	αίματος	
συλλέχθηκαν	σε	διάφορους	χρόνους	μέχρι	και	24	ώρες	μετά	τη	χορήγηση	του	φαρμάκου.	Η	μέθοδος	της	υγροχρωματογραφίας	
υψηλής	 απόδοσης	 (HPLC)	 χρησιμοποιήθηκε	 για	 τον	 προσδιορισμό	 των	 συγκεντρώσεων	 της	 τυλοσίνης	 στο	 πλάσμα.	Η	
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USA)	was	 used	 for	 intravenous	 injection.	The	drug	




of	 35-40	days	 old,	weighing	 from	1.7	 -	 2.0kg	were	
used	in	this	study.	The	chickens	were	purchased	from	
local	 poultry	 farm.	They	were	 placed	 in	 the	 animal	
house	at	Jordan	University	of	Science	and	Technology	
(JUST).	The	animals	were	monitored	for	2	weeks	for	
any	 apparent	 clinical	 signs	 of	 disease	 before	 drug	
administration.	 The	 animal	 house	 temperature	was	
maintained	at	25	±	2°C	and	humidity	at	45–65%.	The	
chickens	had	 free	 access	 to	water	 and	 antibacterial-
free	food	(consisted	of	maize,	soybean,	and	premix)	
ad	libitum	daily.	









of	 group	 3	 (n=15)	was	 given	 a	 single	 intravenous	
dose	of	 standard	 tylosin	powder	 (25	mg/kg	b.w.)	 in	

















Analytical method and sample preparation
The	High	Performance	Liquid	Chromatography	
(HPLC)	method	has	 been	modified	 from	previously	










The	 chromatographic	 separation	was	 performed	
using	a	purospher	Star	RP-18e	(5	μm,	125	mm	×	4.6	
mm)	 column	 (Merck,	Germany)	with	 an	 isocratic	








Calibration curve and validation procedure
A	 standard	 calibration	 curve	was	 prepared	 by	
adding	20	μl	of	tylosin	(1	mg/ml)	to	980	μl	antibacterial-
free	 chicken	 plasma.	This	was	 further	 diluted	 into	
antibacterial-free	chicken	plasma	to	produce	standard	
of	0.025,	0.05,	0.1,	1,	5,	10,	25	and	50	μg/ml.	Standard	






The	HPLC	method	was	 validated	 by	 assessing	
linearity,	 precision,	 recovery	 and	 sensitivity.	 Two	
standard	 calibration	 curves	with	 8	 concentrations	




over	 the	 range	 of	 0.025-50	μg/ml	 (r2>0.9996).	The	












Pharmacokinetic and statistical analysis 
The	 pharmacokinetic	 analysis	 of	 the	 data	was	
performed	 using	 non-compartmental	method	 based	
on	 statistical	moment	 theory	 (SMT)	 according	 to	
previously	 described	method	 (Gibaldi	 and	 Perrier	
1982),	 	 using	 the	 commercially	 available	 	 software	
(Win	Nonlin®,	Pharsight	Corporation,	Cary,	NC,	USA).	
The	 calculated	 parameters	were:	 area	 under	 plasma	
concentration-time	 curve	 (AUC)	 and	 the	 area	 under	
the	moment	 curve	 (AUMC)	 using	 linear	 trapezoid	






to	 infinity,	 by	 adding	 the	 ratio	Clast/kel;	 elimination	
half-life	 (t1/2β),	where	 t1/2β	 =	 0.639/	 kel	 ;	 total	 body	









Differences	 between	 the	 pharmacokinetic	
parameters	 of	 the	 two	 tested	 formulations	 were	
evaluated	by	one-way	analysis	of	variance	(ANOVA)	
using	 the	 commercially	 available	 software	 package	




All	 chickens	 used	 in	 the	 present	 study	 were	
clinically	healthy	throughout	the	experimental	period	

















The	 concentrations	 of	 tylosin	 in	 chicken	plasma	
were	 determined	 up	 to	 12	 h	 and	 were	 below	 the	
detectable	 limit	 in	 all	 chickens	 24	 h	 post	 single	




2.30±0.38	h,	 respectively	 for	Tylosina®	 and	Tylan®.	
The	mean	concentration–time	profile	for	tylosin	oral	
products	is	shown	in	Figure	1.
The	 oral	 bioavailability	 (F)	 for	 Tylosina®	 and	
Tylan®	 were	 40.56	 and	 35.41%,	 respectively	 and	
the	 relative	 bioavailability	was	113.9	%	 (Tylosina®/
Tylan®).	 The	 pharmacokinetics	 parameters	 after	




that	 achieves	 good	 tissue	 and	 barrier	 penetration,	




attains	 higher	 concentration	 at	 the	 tissue	 compared	





Cmax, maximum plasma concentration; tmax, time to peak concentration; t1/2β, elimination half-life; AUC 0-12h, area under 
plasma concentration-time curve from zero to 12 h post drug administration; AUC 0-∞, area under plasma concentration-
time curve from zero to infinity; MRT, mean residence time; F, systemic bioavailability; ClB/F, total body clearance/F; 
Vdz/F, volume of distribution/F.





level	 of	 10	mg/kg	 b.w.	 (1.2±0.2	 μg/ml)	 (Kowalski	
et	 al.,	 2002).	 The	 difference	 in	Cmax	 (2.2-2.5	 x)	 is	
expected	since	 the	administered	dosage	 in	our	study	
is	2.5	x	higher.	On	the	other	hand,	the	reported	tmax	in	
this	 experiment	was	 2.36±0.42	 and	2.30±0.38	h	 for	
Tylosina®	and	Tylan®,	respectively.	These	values	were	
longer	than	those	reported	in	broiler	chickens	(1.5±0.3	
h)	 (Kowalski	 et al.	 2002).	 The	 oral	 bioavailability	
(F)	 for	 tylosin	 represented	 by	Tylosina®	 (40.56%)	
and	Tylan®	(35.41	%)	was	slightly	higher	than	those	




AUC0-∞,	 Cmax	 for	 The	 two	 oral	 formulations	were	
not	significantly	different,	indicating	that	the	plasma	
profiles	 produced	 by	 Tylosina®	 are	 comparable	
to	 those	 produced	 by	 Tylan®.	 Moreover,	 no	
significant	 differences	were	 found	 among	 all	 tested	




inhibitory	 concentration	 (MIC)	values	 ranging	 from	
0.01	 to	 0.5	 μg/ml	 for	 various	 susceptible	 bacterial	
and	mycoplasmal	 pathogens	 (Jordan	 and	Horrocks	
1996,	Hannan	et	al.	1997,	Jordan	et	al.	1998,	Salmon	
and	Watts	2000).	Tylosin	(Tylosina®	and	Tylan®)	was	
detected	 in	 chicken	plasma	 at	 concentrations	 higher	
than	the	MIC	for	most	susceptible	microorganisms	and	
Mycoplasma	 for	12	h	 following	oral	administration.	
Therefore,	 oral	 tylosin	 administration	 at	 a	 dose	 of	
25	mg/kg	 b.w.	 seems	 to	 be	 a	 suitable	 therapeutic	
dose	in	broiler	chickens.	However,	repeated	doses	are	






detected	 in	 plasma	 (Kowalski	 	 et	 al.	 2002,	Giguere	
2006).	Despite	the	extensive	use	of	tylosin	in	poultry	
industry,	 limited	 information	 is	 currently	 available	
about	the	mathematical	disposition	of	tylosin	in	broiler	
















The	 clearance	 obtained	 in	 the	 present	 study	
(28.29±2.86	ml/min/kg)	was	higher	than	those	reported	
in	 chickens	 (5.30±0.59	ml/min/kg)	 (Kowalski	 et	 al.	
2002)	and	in	sheep	and	goat	(6.89±0.94	and	8.66±1.37	
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